---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-269959"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-09-10T23:59:59+00:00"
generated_at: "2026-06-29T04:39:18.522940+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition

## Summary
- Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.
- Net proceeds ~$2.28B to partially fund $5.7B BioLegend acquisition announced July 25, 2021.
- Special mandatory redemption at 101% if BioLegend deal not closed by Jan 31, 2022.
- Bridge loan commitments reduced to $514M after net proceeds.
- Notes are general unsecured, rank equally with other unsecured debt.

## SEC filing metadata
- accession: 0001193125-21-269959
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-09-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/0001193125-21-269959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/d204305d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-269959
- JSON: https://secwatch.observer/filing/0001193125-21-269959.json
- Plain text: https://secwatch.observer/filing/0001193125-21-269959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.